Atai Life Sciences Stock Price, News & Analysis (NASDAQ:ATAI) $1.12 +0.08 (+7.69%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.03▼$1.1550-Day Range$1.04▼$1.5252-Week Range$1.03▼$3.65Volume1.07 million shsAverage Volume747,515 shsMarket Capitalization$185.93 millionP/E RatioN/ADividend YieldN/APrice Target$12.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Atai Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,042.9% Upside$12.80 Price TargetShort InterestHealthy4.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.22Based on 3 Articles This WeekInsider TradingAcquiring Shares$81,200 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.50 out of 5 starsMedical Sector128th out of 951 stocksPharmaceutical Preparations Industry42nd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.80, Atai Life Sciences has a forecasted upside of 1,042.9% from its current price of $1.12.Amount of Analyst CoverageAtai Life Sciences has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.46% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Atai Life Sciences has recently decreased by 9.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATAI. Previous Next 3.5 News and Social Media Coverage News SentimentAtai Life Sciences has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Atai Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.MarketBeat Follows9 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $81,200.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders30.00% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.16% of the stock of Atai Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atai Life Sciences are expected to remain at ($0.69) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Atai Life Sciences Stock (NASDAQ:ATAI)ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More ATAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATAI Stock News HeadlinesNovember 29, 2023 | seekingalpha.comAtai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash ValueNovember 17, 2023 | msn.comatai Life Sciences N.V. (ATAI) Upgraded to Buy: Here's WhyDecember 2, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 14, 2023 | finance.yahoo.comATAI Life Sciences NV Reports Q3 2023 Financial Results and Pipeline ProgressNovember 14, 2023 | markets.businessinsider.comAtai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026November 14, 2023 | msn.comATAI Life Sciences GAAP EPS of $0.25November 14, 2023 | finance.yahoo.comatai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline HighlightsOctober 31, 2023 | morningstar.comATAI Life Sciences NV ATAIDecember 2, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 29, 2023 | benzinga.comPsyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And MoreOctober 10, 2023 | finance.yahoo.comATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORTOctober 6, 2023 | finance.yahoo.comatai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitOctober 5, 2023 | msn.comATAI Life Sciences N.V. (ATAI) Price Target Increased by 5.04% to 12.57October 3, 2023 | benzinga.comAtai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT FormulationOctober 2, 2023 | finance.yahoo.comatai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsOctober 2, 2023 | finance.yahoo.comatai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsSeptember 19, 2023 | msn.comWhy I Wrote a (First-Hand) Guide to the New Age of PsychedelicsSeptember 15, 2023 | finance.yahoo.comInsider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NVSeptember 14, 2023 | finance.yahoo.comatai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 13, 2023 | uk.finance.yahoo.comAtai Life Sciences N.V. (ATAI)September 12, 2023 | markets.businessinsider.comNY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 YearsSeptember 6, 2023 | msn.comatai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSeptember 1, 2023 | seekingalpha.comAtai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved TherapiesAugust 21, 2023 | msn.comDown -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)August 13, 2023 | benzinga.comATAI Life Sciences Stock (NASDAQ:ATAI), Guidance and ForecastAugust 12, 2023 | benzinga.comATAI Life Sciences Stock (NASDAQ:ATAI), Short Interest ReportAugust 11, 2023 | markets.businessinsider.comATAI Life Sciences (ATAI) Receives a Buy from Berenberg BankSee More Headlines Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2023Today12/02/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$12.80 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+1,042.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,380,000.00 Net Margins-20,043.11% Pretax Margin-18,050.30% Return on Equity-54.90% Return on Assets-47.37% Debt Debt-to-Equity Ratio0.06 Current Ratio10.96 Quick Ratio10.96 Sales & Book Value Annual Sales$334,000.00 Price / Sales556.68 Cash FlowN/A Price / Cash FlowN/A Book Value$1.62 per share Price / Book0.69Miscellaneous Outstanding Shares166,010,000Free Float116,207,000Market Cap$185.93 million OptionableNot Optionable Beta0.69 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Christian Angermayer (Age 45)Founder & Chairman of the Supervisory Board Comp: $70kMr. Florian Brand (Age 36)Co-founder & CEO Comp: $835.44kDr. Srinivas G. Rao M.D. (Age 54)Ph.D., Co-Founder & Chief Scientific Officer Comp: $834.15kMr. Stephen B. Bardin (Age 33)MD & CFO (Leave of Absence) Comp: $651.32kMs. Anne JohnsonChief Accounting Officer & Interim CFODr. Michael Raven Ph.D.Senior Vice President of OperationsMr. Frank Stegert (Age 42)Vice President of Investment & Venture Management Mr. Ryan BarrettSenior VP, General Counsel & Corporate SecretaryDr. Glenn Short Ph.D.Senior Vice President of Early DevelopmentDr. Sahil V. Kirpekar M.D. (Age 38)Chief Business Officer More ExecutivesKey CompetitorsBioVieNASDAQ:BIVIArcutis BiotherapeuticsNASDAQ:ARQTMersana TherapeuticsNASDAQ:MRSNCorMedixNASDAQ:CRMDscPharmaceuticalsNASDAQ:SCPHView All CompetitorsInsiders & InstitutionsAmerican Century Companies Inc.Bought 12,756 shares on 11/30/2023Ownership: 0.029%Florian BrandBought 20,000 shares on 11/16/2023Total: $23,200.00 ($1.16/share)Legal & General Group PlcSold 30,783 shares on 11/15/2023Ownership: 0.036%Qube Research & Technologies LtdSold 8,426 shares on 11/14/2023Ownership: 0.016%HighTower Advisors LLCSold 14,400 shares on 11/8/2023Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions ATAI Stock Analysis - Frequently Asked Questions Should I buy or sell Atai Life Sciences stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATAI shares. View ATAI analyst ratings or view top-rated stocks. What is Atai Life Sciences' stock price target for 2024? 4 equities research analysts have issued 1 year price targets for Atai Life Sciences' shares. Their ATAI share price targets range from $9.00 to $20.00. On average, they anticipate the company's stock price to reach $12.80 in the next year. This suggests a possible upside of 1,042.9% from the stock's current price. View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts. How have ATAI shares performed in 2023? Atai Life Sciences' stock was trading at $2.66 on January 1st, 2023. Since then, ATAI shares have decreased by 57.9% and is now trading at $1.12. View the best growth stocks for 2023 here. Are investors shorting Atai Life Sciences? Atai Life Sciences saw a decrease in short interest in November. As of November 15th, there was short interest totaling 5,090,000 shares, a decrease of 9.6% from the October 31st total of 5,630,000 shares. Based on an average daily trading volume, of 526,800 shares, the short-interest ratio is presently 9.7 days. Currently, 4.5% of the shares of the company are short sold. View Atai Life Sciences' Short Interest. When is Atai Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024. View our ATAI earnings forecast. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The business had revenue of $0.17 million for the quarter. Atai Life Sciences had a negative trailing twelve-month return on equity of 54.90% and a negative net margin of 20,043.11%. What ETFs hold Atai Life Sciences' stock? ETFs with the largest weight of Atai Life Sciences (NASDAQ:ATAI) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Moonshot Innovators ETF (MOON).Simplify Propel Opportunities ETF (SURI). What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO). When did Atai Life Sciences IPO? (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Atai Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (0.38%), AdvisorShares Investments LLC (0.11%), Legal & General Group Plc (0.04%), American Century Companies Inc. (0.03%), HighTower Advisors LLC (0.03%) and Qube Research & Technologies Ltd (0.02%). Insiders that own company stock include Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ATAI) was last updated on 12/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.